Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Clinical evidence

ESK-001-002

13 evidence topics · 2 sources

Objective
Location and study date
Recruitment and results status in the ClinicalTrials.gov record
FieldQuoted record
Overall status“Completed”
Results“No Results Posted”
Last update posted“2023-05-09”
Study design
Eligibility criteria
Inclusion and exclusion criteria in the ClinicalTrials.gov record
CriterionQuoted record
Inclusion: age and health“Healthy Men and woman age 18-60”
Inclusion: consent“Able to provide written informed consent”
Inclusion: pregnancy and lactation“Females can not be pregnant or lactating”
Exclusion: prior exposure“Prior exposure to ESK-001”
Exclusion: malignancy“History of malignancy within the last 10 years”
Exclusion: viral infection“Positive for HIV, Hepatitis B or C”
Exclusion: tuberculosis“History of tuberculosis”
Exclusion: alcohol or drugs“Positive test for alcohol or drugs”
Ages eligible for study“18 Years to 60 Years (Adult )”
Sexes eligible for study“All”
Accepts healthy volunteers“Yes”
Treatment
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • The relative bioavailability, food effect, and gastric acid reduction comparisons (liquid, tablet fasted, tablet fed, and tablet with rabeprazole) have no posted results, and the report holds no published results; the ClinicalTrials.gov record reads “No Results Posted”.
  • The study was a single-center, open-label crossover study; the registered description calls it partly randomized and plans 15 healthy participants, and actual enrollment was 14.
  • Each participant received a single dose on 4 occasions, so the comparisons rest on single-dose pharmacokinetics in healthy adults aged 18 to 60 years.